Subgroup analyses of the PHOTON trial show visual acuity gains across subgroups by race, baseline visual acuity and retina ...

Steven Levine, MD: How might a payer flag a patient who’s receiving a medication like intranasal esketamine [Spravato] that requires high touch to support access and reduce delay to therapy? What are ...

A new statistical models shed light on why some patients can extend the dosing interval with Eylea (aflibercept) from 8 weeks ...

Changes have been proposed to the quality payment program that could have ups and downs, but not, perhaps for some, until ...

Stephanie Graff, M.D., FACP, FASCO, director of breast oncology at the Lifespan Cancer Institute and author of Investigating the Salience of Clinical Meaningfulness and Clinically Meaningful Outcomes ...

University of Washington’s Peter Rabinowitz, M.D., M.P.H.. sees a world awash in emerging diseases and climate change data ...

The list includes dengue fever, chikungunya, leptospirosis and Valley fever, says University of Washington professor Peter ...

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...

Clinical and other trials for GLP-1 therapies have found an association between these drugs and diabetic retinopathy ...

Rapid weight loss from the glucagon-like peptide 1 (GLP-1s) can reduce fat tissue in face that makes for a smooth, more ...

Technology can help address the complexities of specialty medications by automating processes and enabling proactive interventions to ensure patients stay on their critical therapies, according to ...

Up to half of patients showed significant improvement in study results presented at the American Academy of Ophthalmology ...